Tetrabenazine in the treatment of Huntington's chorea
- PMID: 132600
Tetrabenazine in the treatment of Huntington's chorea
Abstract
The effectiveness of tetrabenazine in controlling choreic movement in Huntington's chorea has been confirmed in a long-term study. Side effects noted included postural hypotension, dysphagia and pneumonia. Careful supervision of patients taking this effective agent is urged.
Similar articles
-
Short-term effects of tetrabenazine on chorea associated with Huntington's disease.Mov Disord. 2007 Jan;22(1):10-3. doi: 10.1002/mds.21161. Mov Disord. 2007. PMID: 17078062 Clinical Trial.
-
Tetrabenazine in the treatment of Huntington's chorea and other hyperkinetic movement disorders.J Clin Psychiatry. 1978 Jan;39(1):81-7. J Clin Psychiatry. 1978. PMID: 147268
-
Role of tetrabenazine for Huntington's disease-associated chorea.Ann Pharmacother. 2010 Jun;44(6):1080-9. doi: 10.1345/aph.1M582. Epub 2010 May 4. Ann Pharmacother. 2010. PMID: 20442355 Review.
-
The long-term effect of tetrabenazine in the management of Huntington disease.Clin Neuropharmacol. 2008 Nov-Dec;31(6):313-8. doi: 10.1097/WNF.0b013e318166da60. Clin Neuropharmacol. 2008. PMID: 19050408
-
Tetrabenazine in the treatment of hyperkinetic movement disorders.Expert Rev Neurother. 2006 Jan;6(1):7-17. doi: 10.1586/14737175.6.1.7. Expert Rev Neurother. 2006. PMID: 16466307 Review.
Cited by
-
International Guidelines for the Treatment of Huntington's Disease.Front Neurol. 2019 Jul 3;10:710. doi: 10.3389/fneur.2019.00710. eCollection 2019. Front Neurol. 2019. PMID: 31333565 Free PMC article.
-
Epidemiology and dysphagia.Dysphagia. 1994 Fall;9(4):209-17. doi: 10.1007/BF00301912. Dysphagia. 1994. PMID: 7805418 Review.
-
VMAT2 Inhibitors in Neuropsychiatric Disorders.CNS Drugs. 2018 Dec;32(12):1131-1144. doi: 10.1007/s40263-018-0580-y. CNS Drugs. 2018. PMID: 30306450 Review.
-
Tetrabenazine in the treatment of Huntington's disease.Neuropsychiatr Dis Treat. 2007;3(5):545-51. Neuropsychiatr Dis Treat. 2007. PMID: 19381278 Free PMC article.